Orexigen's Contrave:
i never liked contrave, and i still think it's going to face a hard time at the FDA.
But nevertheless, here are the abstracts for the upcoming Obesity Meeting next week:
The Obesity Society Annual Scientific Meeting, Phoenix Convention Center
Saturday, October 4
Poster Presentation
Abstract: 317-P
Title: "The Naltrexone-Bupropion Combination Reduces the Prevalence of the
Metabolic Syndrome and Improves Cardiometabolic Markers in At-Risk
Subjects"
Time: 5:00-7:00 p.m. MT
Sunday, October 5
Symposium
Event Code: E1280
Title: "Reward and Obesity; Too Much of a Good Thing?"
Time: 6:15-7:45 a.m. MT
Location: Hyatt Regency Phoenix, Regency Ballroom A/B
Oral Presentation
Abstract: 61-OR
Presenter: Ronald Landbloom, M.D.
Title: "Long Term Weight Loss from a Dose Optimization Study with
Zonisamide SR and Bupropion SR"
Time: 11:00-11:15 a.m. MT
Poster Presentation
Abstract: 585-P
Title: "Relative Bioavailability of Sustained-release (SR) versus
Immediate-release (IR) Naltrexone (NAL) Formulations in Healthy Obese
Volunteers: Implications for Improved Tolerability?"
Time: 5:30-7:30 p.m. MT
Monday, October 6
Oral Presentation
Abstract: 104-OR
Presenter: Sonja K. Billes, Ph.D.
Title: "Leptin Regulates Food Intake Via Dopamine Receptor-Dependent
Mechanisms"
Time: 11:30-11:45 a.m. MT
Poster Presentation
Abstract: 847-P
Title: "Quality of Life Improvements from a Dose Optimization Study with
Zonisamide SR and Bupropion SR"
Time: 12:45-2:45 p.m. MT
Poster Presentation
Abstract: 848-P
Title: "Timing of Response from a Dose Optimization Study with Zonisamide
SR and Bupropion SR"
Time: 12:45-2:45 p.m. MT
Upcoming Corporate Presentations
JMP Securities Healthcare Sector Focus Conference
Le Parker Meridien, New York
October 6, 2008
10:00 a.m. ET
BIOCOM Investor Conference
Hyatt Regency La Jolla, San Diego
October 28, 2008
4:00 p.m. PT
AI
